Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 318

Similar articles for PubMed (Select 16763281)

1.

Epidermal growth factor receptor biology in head and neck cancer.

Kalyankrishna S, Grandis JR.

J Clin Oncol. 2006 Jun 10;24(17):2666-72. Review.

PMID:
16763281
2.

Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma.

Kao J, Sikora AT, Fu S.

Curr Cancer Drug Targets. 2009 Dec;9(8):931-7. Review.

PMID:
20025602
3.
4.

Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.

Uribe P, Gonzalez S.

Pathol Res Pract. 2011 Jun 15;207(6):337-42. doi: 10.1016/j.prp.2011.03.002. Epub 2011 Apr 29. Review.

PMID:
21531084
5.

Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma.

Thomas SM, Bhola NE, Zhang Q, Contrucci SC, Wentzel AL, Freilino ML, Gooding WE, Siegfried JM, Chan DC, Grandis JR.

Cancer Res. 2006 Dec 15;66(24):11831-9.

7.
8.

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.

Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR.

Clin Cancer Res. 2006 Sep 1;12(17):5064-73.

9.

Molecular therapy in head and neck oncology.

Bernier J, Bentzen SM, Vermorken JB.

Nat Rev Clin Oncol. 2009 May;6(5):266-77. doi: 10.1038/nrclinonc.2009.40. Review.

PMID:
19390553
11.

Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells.

Mantha AJ, McFee KE, Niknejad N, Goss G, Lorimer IA, Dimitroulakos J.

J Cancer Res Clin Oncol. 2003 Nov;129(11):631-41. Epub 2003 Aug 26.

PMID:
12942316
12.

Epidermal growth factor receptor-stimulated activation of phospholipase Cgamma-1 promotes invasion of head and neck squamous cell carcinoma.

Thomas SM, Coppelli FM, Wells A, Gooding WE, Song J, Kassis J, Drenning SD, Grandis JR.

Cancer Res. 2003 Sep 1;63(17):5629-35.

13.

Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer.

Astsaturov I, Cohen RB, Harari P.

Expert Rev Anticancer Ther. 2006 Sep;6(9):1179-93. Review.

PMID:
17020453
14.

Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer.

Pernas FG, Allen CT, Winters ME, Yan B, Friedman J, Dabir B, Saigal K, Mundinger GS, Xu X, Morris JC, Calvo KR, Van Waes C, Chen Z.

Clin Cancer Res. 2009 Apr 1;15(7):2361-72. doi: 10.1158/1078-0432.CCR-08-1011. Epub 2009 Mar 24.

16.

Epidermal growth factor receptor-targeted molecular therapeutics for head and neck squamous cell carcinoma.

Egloff AM, Grandis J.

Expert Opin Ther Targets. 2006 Oct;10(5):639-47.

PMID:
16981821
17.

The role of epidermal growth factor receptor in head and neck squamous cell carcinoma.

Pomerantz RG, Grandis JR.

Curr Oncol Rep. 2003 Mar;5(2):140-6. Review.

PMID:
12583831
18.

Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor.

Mandic R, Rodgarkia-Dara CJ, Krohn V, Wiegand S, Grénman R, Werner JA.

Anticancer Res. 2009 Apr;29(4):1181-7.

19.

The role of cetuximab in the treatment of squamous cell cancer of the head and neck.

Burtness B.

Expert Opin Biol Ther. 2005 Aug;5(8):1085-93. Review.

PMID:
16050785
20.

Mechanisms of resistance to EGFR inhibitors in head and neck cancer.

Cooper JB, Cohen EE.

Head Neck. 2009 Aug;31(8):1086-94. doi: 10.1002/hed.21109. Review.

PMID:
19378324
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk